MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP) in a report released on Sunday. The brokerage issued a buy rating on the stock.

MEI Pharma Stock Performance

Shares of MEI Pharma stock opened at $2.82 on Friday. MEI Pharma has a 1 year low of $2.61 and a 1 year high of $6.91. The company has a market capitalization of $18.78 million, a P/E ratio of -0.40 and a beta of 0.83. The company’s fifty day moving average is $2.87 and its two-hundred day moving average is $3.00.

MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.20) earnings per share (EPS) for the quarter. As a group, equities analysts expect that MEI Pharma will post -5.1 earnings per share for the current year.

Institutional Trading of MEI Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. World Investment Advisors LLC purchased a new stake in shares of MEI Pharma in the third quarter valued at about $71,000. Corsair Capital Management L.P. purchased a new stake in shares of MEI Pharma in the third quarter valued at about $69,000. Finally, National Bank of Canada FI boosted its holdings in shares of MEI Pharma by 43.5% in the second quarter. National Bank of Canada FI now owns 33,000 shares of the company’s stock valued at $94,000 after acquiring an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 52.38% of the company’s stock.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.